1044518-75-3

Usage

Uses

Used in Pharmaceutical Industry:
(4R-cis)-6-formyl-2,2-dimethyl-1,3-dioxane-4-acetic acid tert-butyl ester is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
(4R-cis)-6-formyl-2,2-dimethyl-1,3-dioxane-4-acetic acid tert-butyl ester is used as a versatile reagent in organic synthesis. Its formyl and ester groups can be utilized in various chemical reactions, such as reduction, oxidation, and esterification, to produce a wide range of organic compounds with diverse applications.
Used in the Synthesis of Amphotericin B:
(4R-cis)-6-formyl-2,2-dimethyl-1,3-dioxane-4-acetic acid tert-butyl ester is used as a key intermediate in the synthesis of Amphotericin B, a potent antifungal drug. Its unique structure and functional groups play a crucial role in the formation of the final product, contributing to the drug's efficacy against various fungal infections.

Upstream product

• 144-55-8 sodium hydrogencarbonate 
• 148809-28-3 [(4S,6R)-2,2-dimethyl-6-hydroxymethyl-1,3-dioxan-4-yl]acetic acid t-butyl ester 

Downstream Products

• 1044518-76-4 tert-butyl 2-[(4S,6R)-6-((R)-3-((4S,6S)-6-(2-(benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)-1-hydroxyprop-2-ynyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate 
• 289042-12-2 2-[(4R,6S)-6-[(E)-2-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidin-5-yl]vinyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid tert butyl ester 
• 1378943-63-5 C₂₉H₄₀FN₃O₆S 

Relevant academic research and scientific papers

A statin intermediate and its derivatives

The invention discloses a preparation method of a statin intermediate and derivatives thereof. The preparation method comprises the steps of: preparing to obtain a compound in a formula (II) through oxidation reaction among a compound in a formula IV, DMSO (dimethylsulphoxide) and alkali in the existence of an alkali metal salt catalyst, and obtaining a compound in a formula (I) by base catalysis through condensation of the compound in the formula (II) and a compound in a formula (III), wherein in the formulas, X is halogens, R is substituted or non-substituted alkyl groups of C1-C6 and alkane cyclic groups or aryl groups of C3-C5, substituent groups of R are the aryl groups, and R1 is selected from one or several of the alkyl groups of C1-C6 and the halogens. Compared with the prior art, the preparation method has the advantages that the compound in the formula IV is not esterified and hydrolyzed for preparing alcohol, then aldehyde (compound in the formula II) is prepared through oxidation, and the compound in the formula II is directly prepared from the compound in the formula IV in one step. The preparation method has the advantages of short steps, simple operation and suitability for industrial production.

Synthesis and biophysical studies on 35-Deoxy amphotericin b methyl ester

The use of molecular editing in the elucidation of the mechanism of action of amphotericin B is presented. A modular strategy for the synthesis of amphotericin B and its designed analogues is developed, which relies on an efficient gram-scale synthesis of various subunits of amphotericin B. A novel method for the coupling of the mycosa-mine to the aglycone was identified. The implementation of the approach has enabled the preparation of 35-deoxy amphotericin B methyl ester. Investigation of the antifungal activity and efflux-inducing ability of this amphotericin B congener provided new clues to the role of the 35-hydroxy group and is consistent with the involvement of double barrel ion channels in causing electrolyte efflux. 2009 Wiley-VCH Verlag GmbH & Co. KGaA.

Synthesis of 35-deoxy amphotericin B methyl ester: A strategy for molecular editing

(Chemical Presented) A modular strategy for the assembly of amphotericin B analogues with modifications in the macrolactone ring relies on the efficient gram-scale synthesis of all major and minor motifs of amphotericin B. Proof of concept has been achieved by the preparation of the 35-deoxy aglycone en route to the long-sought-after 35-deoxy analogue of amphotericin B.